Current and emerging treatment options for endometriosis

被引:120
|
作者
Ferrero, Simone [1 ,2 ]
Evangelisti, Giulio [1 ,2 ]
Barra, Fabio [1 ,2 ]
机构
[1] Osped Policlin San Martino, Acad Unit Obstet & Gynecol, Largo R Benzi 10, I-16132 Genoa, Italy
[2] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy
关键词
Endometriosis; combined oral contraceptives; progestins; gonadotropin-releasing hormone agonist; aromatase inhibitors; gonadotropin-releasing hormone antagonist; anti-angiogenetic; anti-oxidant; immunomodulators; DEPOT MEDROXYPROGESTERONE ACETATE; CHRONIC PELVIC PAIN; NECROSIS-FACTOR-ALPHA; ESTROGEN-RECEPTOR MODULATOR; ONLY CONTRACEPTIVE PILL; ORAL GNRH ANTAGONIST; LEUPROLIDE ACETATE; DOUBLE-BLIND; RECTOVAGINAL ENDOMETRIOSIS; NORETHISTERONE ACETATE;
D O I
10.1080/14656566.2018.1494154
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Pharmacotherapy has a pivotal role in the management of endometriosis with long-term treatments balancing clinical efficacy (control of pain symptoms and prevention of recurrence of the disease after surgery) with an acceptable safety profile. Treatment choice is based on several factors including age and patient preference, reproductive plans, intensity of pain, severity of disease and incidence of adverse effects. Areas covered: The aim of this review is to provide the reader with a complete overview of drugs that are currently available or are under investigation for the treatment of endometriosis highlighting on-going clinical trials. Expert opinion: Almost all of the available treatment options for endometriosis suppress ovarian function and are not curative. Combined oral contraceptives and progestins are commonly administered to these patients in order to ameliorate pain symptoms. Gonadotropin-releasing hormone-agonists are prescribed when first-line therapies are ineffective, not tolerated or contraindicated. Aromatase inhibitors should be reserved only for women who are refractory to other treatments. Amongst the drugs under development, gonadotropin-releasing hormone antagonists have shown the most promising results. Presently, are a number of potential therapies currently in pre-clinical or early clinical studies which may alter treatment strategies in the future although further studies are necessary.
引用
收藏
页码:1109 / 1125
页数:17
相关论文
共 50 条
  • [21] Current and Emerging Options for the Drug Treatment of Narcolepsy
    De la Herran-Arita, Alberto K.
    Garcia-Garcia, Fabio
    DRUGS, 2013, 73 (16) : 1771 - 1781
  • [22] Treatment of pemphigus vulgaris - Current and emerging options
    Yeh, SW
    Sami, N
    Ahmed, RA
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2005, 6 (05) : 327 - 342
  • [23] Current and emerging treatment options for uveal melanoma
    Pereira, Patricia Rusa
    Odashiro, Alexandre Nakao
    Lim, Li-Anne
    Miyamoto, Cristina
    Blanco, Paula L.
    Odashiro, Macanori
    Maloney, Shawn
    De Souza, Dominique F.
    Burnier, Miguel N., Jr.
    CLINICAL OPHTHALMOLOGY, 2013, 7 : 1669 - 1682
  • [24] Current and emerging pharmacological treatment options for dementia
    Ringman, JM
    Cummings, JL
    BEHAVIOURAL NEUROLOGY, 2006, 17 (01) : 5 - 16
  • [25] Current and emerging treatment options for postmenopausal osteoporosis
    Maxwell, Angie Eaton
    Maclayton, Darego
    Nguyen, Huong
    FORMULARY, 2008, 43 (05) : 166 - +
  • [26] Current and emerging treatment options for nasopharyngeal carcinoma
    Spratt, Daniel E.
    Lee, Nancy
    ONCOTARGETS AND THERAPY, 2012, 5 : 297 - 308
  • [27] Current and Emerging Treatment Options for Uterine Fibroids
    Mohamed Ali
    Michał Ciebiera
    Marta Wlodarczyk
    Samar Alkhrait
    Elise Maajid
    Qiwei Yang
    Shih-Min Hsia
    Ayman Al-Hendy
    Drugs, 2023, 83 : 1649 - 1675
  • [28] Proliferative vitreoretinopathy: an update on the current and emerging treatment options
    Waizel, Maria Della Volpe
    Schlote, Torsten
    Rickmann, Annekatrin
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2023,
  • [29] Proliferative vitreoretinopathy: an update on the current and emerging treatment options
    Lorenzo Ferro Desideri
    Dmitri Artemiev
    Souska Zandi
    Martin S Zinkernagel
    Rodrigo Anguita
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2024, 262 (3) : 679 - 687
  • [30] Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options
    Jiromaru, Rina
    Nakagawa, Takashi
    Yasumatsu, Ryuji
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2681 - 2689